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Abstract
Background: HIV patients on HAART are prone to metabolic abnormalities, including insulin resistance,
lipodystrophy and diabetes. This study purports to investigate the relationship of ethnicity and CD4+ T cell count
attained after stable highly-active antiretroviral treatment (HAART) with glucose metabolism in hyperrtriglyceridemic
HIV patients without a history of diabetes.
Methods: Demographic, anthropometric, clinical, endocrinologic, energy expenditure and metabolic measures
were obtained in 199 multiethnic, healthy but hypertriglyceridemic HIV-infected patients [46% Hispanic, 17%
African-American, 37% Non-Hispanic White (NHW)] on stable HAART without a history of diabetes. The relationship
of glucose and insulin responses to ethnicity, CD4 strata (low (<300/cc) or moderate-to-high (≥ 300/cc)), and their
interaction was determined.
Results: African-Americans had significantly greater impairment of glucose tolerance (P < 0.05) and HbA1c levels
(P < .001) than either Hispanics or NHWs. In multivariate models, after adjusting for confounders (age, sex, HIV/
HAART duration, smoking, obesity, glucose, insulin and lipids), African-Americans and Hispanics had significantly
higher HbA1c and 2-hour glucose levels than NHW’s. Demonstrating a significant interaction between ethnicity and
CD4 count (P = 0.023), African Americans with CD4 <300/cc and Hispanics with CD4 ≥300/cc had the most
impaired glucose response following oral glucose challenge.
Conclusions: Among hypertriglyceridemic HIV patients on HAART, African-Americans and Hispanics are at
increased risk of developing diabetes. Ethnicity also interacts with CD4+ T cell count attained on stable HAART to
affect post-challenge glycemic response.
Keywords: African American, Hispanic, Impaired glucose tolerance, HbA1c, Dyslipidemia
Background
HIV/AIDS affects U.S. minorities disproportionately,
reflecting a change in the distribution of the disease by
racial/ethnic groups since the beginning of the epidemic
[1,2]. The widespread use of highly-active antiretroviral
therapy (HAART) has slowed the progression of HIV in-
fection to AIDS and has reduced associated morbidity
and mortality [3]. However, HIV patients on HAART are
prone to metabolic abnormalities, including insulin re-
sistance, lipodystrophy and diabetes (1). Lipodystrophy -
characterized by peripheral fat loss, visceral fat increase,
hypertriglyceridemia, and low HDL-C - is often associ-
ated with insulin resistance [4,5], a risk factor for devel-
oping diabetes. Although the frequencies of impaired
glucose tolerance (IGT) and diabetes have not been sys-
tematically evaluated in HIV patients of different eth-
nicities and geographic areas, the rates are likely to be
higher than in the general population. An early study of
HIV patients with lipodystrophy and abdominal fat accu-
mulation reported a 35% prevalence of IGT and 8% pre-
valence of diabetes, compared to 5% and 0.5% respectively
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for matched non-HIV controls [4]. The high frequency of
obesity (an independent risk factor for metabolic abnor-
malities and CVD) among HIV/HAART patients has an
inimical effect on their immune reconstitution and body
composition [6].
Diabetes and cardiometabolic syndrome are highly pre-
valent among ethnic minorities in non-HIV infected pop-
ulations [7]. The relationship between HbA1c and fasting
serum glucose is not homogenous across racial/ethnic
groups: e.g., African-Americans and Hispanics have higher
HbA1c than non-Hispanic Whites (NHWs) after adjusting
for fasting glucose concentration, glucose area under the
curve after oral glucose, insulin response and insulin re-
sistance [8,9]. Possible important interactions between
ethnicity and specific aspects of glucose metabolism may
be obscured in epidemiologic studies that utilize limited
parameters (e.g., only fasting serum glucose, or HbA1c) to
measure dysglycemia: e.g., significant differences have
been noted in HbA1c levels between African-Americans
and NHWs at elevated serum glucose levels [8]. Among
HIV patients, elevated HbA1c has been associated with
higher CD4 cell count, older age, and ethnicity [10]. Simi-
lar data from relatively small studies and heterogeneous
HIV populations suggest that metabolic (including gly-
cemic) abnormalities among HIV patients may also be
affected by ethnicity [11,12]. However, in the context of
diabetes risk, the relationship of ethnicity and its interac-
tions with metabolic parameters and the degree of im-
mune reconstitution following HAART have not been
investigated systematically in HIV patients.
The purpose of this study was to assess the relation-
ship of ethnicity with several simultaneously measured
glycemic parameters - HbA1c, fasting serum glucose
and insulin, and post-challenge serum glucose and insu-
lin levels - among hypertriglyceridemic HIV patients on
stable HAART who participated in the Heart Positive
study. We hypothesized that ethnicity and CD4 level on
stable HAART would exert an influence on glycemic
regulation in these hypertriglyceridemic but otherwise
healthy HIV patients.
Methods
Heart Positive (Clinicaltrials.gov ID NCT00246376) was
a large multiethnic study of healthy patients with HIV
infection on stable HAART [13]. The primary outcomes
have been reported [13]. The protocol was approved by
the Institutional Review Boards of Baylor College of
Medicine and the two recruitment centers. Written in-
formed consent was obtained (in Spanish or English)
from all subjects prior to their participation.
Subjects
HIV patients with no history of diabetes were recruited
from two HIV centers in Houston: Legacy Community
Health Services and Thomas Street Clinic, Harris County
Hospital District. The sample comprised 202 patients on
stable HAART with hypertriglyceridemia who underwent
complete screening for the Heart Positive study. Racial/
ethnic distribution of the subjects included NHWs,
African Americans, Hispanics, and Native Americans.
Three Native American subjects were excluded from
this analysis due to their small numbers. All subjects
were hypertriglyceridemic (fasting plasma triglyceri-
des >150 mg/dL), on no lipid-lowering or anti-diabetic
medications, on stable HAART for at least 6 months, with
stable CD4 count and viral load, normal kidney and thy-
roid functions, and transaminase (AST / ALT) levels ≤ 2
times upper limit of normal.
Measures
Demographic and clinical variables
Age, gender, ethnicity, number of years since HIV diag-
nosis, protease inhibitor (PI) use, smoking, alcohol use,
drug abuse, and duration of HAART.
Body composition
Was measured by bioelectrical impedance analysis
(Quantum II Analyzer, RJL Systems, Clinton Township,
MI). Body Mass Index and waist and hip circumference
were measured.
Glucose and insulin
Subjects ingested 75 g glucose (SunDex, Fisher Health
Care, Houston, TX) in the morning after a 10 h over-
night fast, with blood sampling at 0 (fasting), 30, 60, 90
and 120 minutes. Plasma glucose was measured by the
glucose oxidase method and insulin by radioimmuno-
assay (Linco, St. Louis, MO). HbA1c was measured by
HPLC at The Methodist Hospital clinical laboratory,
Houston, TX.
CVD risk markers
Total cholesterol, HDL-C and triglyceride profiles were
determined by an automated enzymatic method (Olym-
pus AU400e Analyzer, Center Valley, PA) at the Baylor
Atherosclerosis Core Laboratory (CLIA-CAP certified).
LDL-C was calculated using the Friedewald formula.
Fasting plasma total cholesterol, HDL-C and triglycer-
ides were measured in the Baylor Atherosclerosis Clinical
Laboratory using an Olympus AU400e automated analy-
zer. The median interassay c.v.’s for these assays were < 2–
5%, and the median intra-assay c.v.’s were < 2–8%.
Energy expenditure
Resting energy expenditure (REE) was measured at the
Baylor General Clinical Research Center (GCRC) by indir-
ect calorimetry (Deltratrac, Sensormedics, Fullerton, CA)
and calculated as REE =VO2 x [4.686 + (RQ-0.707) *
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0.361/0.293 [14]. For subjects who could not visit the
GCRC (n = 68), REE was measured using a MedGem
device (Microlife USA, Dunedin, FL) that measures VO2
and calculates REE using a modified Weir equation.
CD4+ T cell count and HIV-1 viral load
CD4 count was measured by flow cytometry. To assess
the relationship of CD4 levels to glucose abnormalities,
subjects were divided into two groups: “low” (<300/cc;
n = 53), and “moderate-high” (≥300/cc; n = 147). The
cutoff of 300/cc was based on the World Health Organi-
zation’s current recommendation to the increase the
threshold for the use of antiretroviral therapy (ART) for
HIV-infected individuals to a CD4 count of ≤350 cells/
cc (from the previous level of ≤200 cells/μL) [15]. In
view of these changes that occurred during the period of
the Heart Positive study, we used a cutoff slightly lower
than that of the WHO to define the CD4 strata. HIV-1
viral load (VL) was measured by LabCorp or Quest
Diagnostics (Madison, NJ) using either of two quantita-
tive real-time PCR assays (routine, with a lower limit of
400 copies/cc, or ultrasensitive, with a lower limit of 50
copies/cc).
VL values measured as <400/cc by the first assay were
assigned a value of 200/cc and all the VL values were
log-transformed prior to analysis.
Statistical analysis
Descriptive measures, chi-square (χ2) analysis and
ANOVA were used to examine associations and diffe-
rences in metabolic, hormonal, anthropometric and cli-
nical parameters by ethnicity and CD4 strata. When
differences in groups were observed, Bonferroni Post-
Hoc analysis was performed to determine which groups
were different from each other. Repeated measures
ANOVA was used to assess the relationship of ethnicity
with glucose measures following the oral challenge. Co-
variates were age, sex, BMI, lean mass, REE/lean mass,
HAART duration, PI usage, HIV duration, fasting glu-
cose level and fasting insulin level. Two-way interactions
between ethnicity and glucose, ethnicity and gender, ethni-
city and age, and ethnicity and CD4 count were included
in the model and removed if non-significant (p > 0.05).
Linear regression was performed with fasting serum
glucose, 2-hour glucose, and HbA1c as outcome var-
iables, and age, sex, BMI, waist, lean mass, REE/lean mass,
HAART duration, PI usage, HIV duration, fasting glucose,
HOMA-IR, systolic and diastolic blood pressure, family
history of diabetes and interactions as independent vari-
ables. To avoid colinearity, BMI and lean mass (and not
waist-hip-ratio and fat mass) were included in the final
model. All statistical analyses were performed using the
Statistical Package for Social Sciences (SPSS) (version
16 .0, SPSS Inc, Chicago).
Results
Table 1 summarizes demographic, anthropometric and
clinical parameters of the patients by ethnicity and CD4
strata. Mean age was 43.6 ± 8.3 years, duration since
HIV diagnosis 9.5 ± 5.9 years, and duration of HAART
5.6 ± 4.4 years. One quarter of the subjects (26%) had
CD4 <300 / ml. Ethnic distribution was 46% Hispanic,
17% African-American and 37% NHW. The majority of
the patients were indigent and uninsured. Plasma HIV-1
viral load was undetectable in 74%. There was no differ-
ence in the frequency of patients with undetectable viral
load with respect to ethnic group or CD4 stratum. Four-
teen subjects had HIV/HCV co-infection. However,
mean fasting glucose was similar between those with
and without the co-infection [P = 0.204].
Hispanics were significantly younger, had shorter HIV
infection duration, fewer years of HAART and lower
systolic blood pressure, and reported a lower rate of
smoking, drug use and family history of diabetes, than
African-Americans or NHWs (based on Bonferroni
Post-Hoc analysis). Furthermore, they had significantly
lower weight, height and body cell mass than African-
Americans or NHWs. African-Americans had significantly
more fat mass than Hispanics or NHWs (P < 0.01). Both
African-Americans and Hispanics had higher BMI and
percent body fat than NHW’s. NHWs had higher res-
ting VCO2, VO2 and REE than Hispanics or African-
Americans (P < 0.001). There were no significant ethnic
diffenences in frequency of PI use or in fasting plasma
levels of lipids, adiponectin, hsCRP, leptin, and free fatty
acids. or.
No significant differences were noted for frequency of
use of first generation PI drugs (indinavir, nelfinavir, sa-
quinavir) compared to more recent PI drugs (atazanavir,
darunavir), or for use of thymidine analogue drugs, with
respect to ethnic group or CD4 stratum. No differences
were noted between the low and moderate-high CD4
groups in demographic / clinical / anthropometric or en-
docrine / hormonal / energy expenditure parameters ex-
cept for a higher frequency of PI use and lower body cell
mass among subjects with moderate-high CD4 count,
higher testosterone level in the low CD4 group, and
higher VO2 with a trend towards higher VCO2 in the
low CD4 group.
Insulin sensitivity and glycemic parameters by ethni-
city and CD4 cell countare presented in Table 1. The
2-hour glucose value in the OGTT differed significantly
by ethnicity but not by CD4 strata. IGT (defined by 2-h
glucose level >140 but <200 mg/dl) was observed in
32% of the subjects - these were significantly older than
those with normal glucose tolerance (P < 0.001). Com-
pared to either Hispanics or NHWs, African-Americans
manifested greater impairment of glucose tolerance, as
indicated by higher 2-hour glucose (P < 0.05) and HbA1c
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Table 1 Demographic, clinical, endocrine, HIV, metabolic, glycemic and insulin sensitivity parameters, by ethnicity and
CD4 strata
Variables Total
(n = 199)
CD4 Count* CD4 Count* F-Value P Ethnicity Ethnicity Ethnicity F-Value/
χ2 value
P
Low
(<300/cc;
n = 53)
Moderate-High
(> = 300; n = 146)
Non Hispanic
White
(n = 74)
African-
American
(n = 33)
Hispanic
(n = 92)
Demographic,
Clinical, HIV
Age 43.6 ± 8.3 43.7 ± 7.6 43.5 ± 8.5 .026 .871 46.9 ± 8.1 45.9 ± 7.1 39.9 ± 7.4 19.449 <.001
HIV duration (y) 9.5 ± 5.9 9.9 ± 6.2 9.4 ± 5.9 .215 .643 12.7 ± 5.9 7.8 ± 5.1 7.4 ± 5.1 21.803 <.001
HAART duration (y) 5.6 ± 4.4 5.3 ± 5.1 5.7 ± 4.1 .417 .519 7.1 ± 5.2 5.1 ± 4.1 4.6 ± 3.5 6.955 .001
PI Drug Use 67.8% 61.0% 86.5% 11.46 .001 73.0% 66.7% 64.1% 1.49 .474
Family History of Diabetes 42.7% 43.1% 42.5% .007 .933 28.4% 36.4% 57.1% 14.48 .001
Smoking 61.8% 65.4% 61.0% .319 .572 75.7% 69.7% 47.8% 14.51 .001
Drug Use 28.1% 28.8% 28.1% .011 .916 35.1% 36.4% 19.6% 6.24 .044
SBP (mm Hg) 128.3 ± 14.4 130.5 ± 15.7 127.5 ± 13.9 1.741 .188 131.5 ± 15.3 130.8 ± 14.9 125.5 ± 13.4 4.050 .019
DBP (mm Hg) 82.4 ± 10.3 83.4 ± 11.4 82 ± 9.9 .730 .394 84.3 ± 11.2 82.1 ± 10.9 81.2 ± 9.3 1.914 .150
Log Viral load 2.41 ± .40 2.41 ± .48 2.41 ± .38 .002 .961 2.36 ± .40 2.48 ± .08 2.41 ± .39 .920 .400
Total Chol. (mg/dL) 211.4 ± 48.5 207.6 ± 43.5 212.8 ± 50.2 .441 .507 218.1 ± 58.1 201.9 ± 42.0 208.3 ± 41.9 1.520 .221
TG (mg/dL) 302 ± 163 321 ± 145 295 ± 169 1.030 .311 323 ± 163 247 ± 118 302 ± 172 2.567 .079
HDL-C (mg/dL) 39.7 ± 8.9 38.1 ± 8.3 40.3 ± 9.2 2.461 .118 39.6 ± 9.5 39.2 ± 10.1 39.9 ± 8.4 .084 .920
Calc. LDL-C(mg/dL) 111.9 ± 40.4 105.3 ± 37.7 114.3 ± 41.2 1.927 .167 113.9 ± 43.7 113.3 ± 33.4 108.7 ± 41.2 .369 .692
Metabolic
FFA (mmol/L ) .32 ± .22 .29 ± .17 .33 ± .24 1.21 .273 .34 ± .25 .30 ± .18 .32 ± .21 .33 .72
Leptin (ng/mL) 6.8 ± 5.9 5.5 ± 4.8 7.2 ± 6.3 3.193 .076 6.3 ± 5.3 8.1 ± 7.1 6.6 ± 5.9 1.02 .364
Adiponectin (μg/mL) 6.67 ± 5.39 7.40 ± 5.81 6.31 ± 5.16 1.00 .319 8.00 ± 6.46 4.90 ± 5.31 6.25 ± 4.0 2.78 .066
hsCRP (mg/L) 3.73 ± 5.48 3.51 ± 5.86 3.80 ± 5.33 .105 .747 3.48 ± 4.67 4.40 ± 5.45 3.67 ± 6.04 0.32 .73
Percent body fat (%) 22.1 ± 8.2 20.5 ± 6.3 22.7 ± 8.8 2.589 .109 19.5 ± 6.8 24.8 ± 8.1 23.3 ± 8.8 5.97 .003
BMI (kg/m2) 26.8 ± 3.5 26.3 ± 3.2 27 ± 3.6 1.735 .189 25.9 ± 3.6 27.7 ± 3.2 27.3 ± 3.5 4.43 .013
Waist circ. (cm) 91.5 ± 11.7 90.2 ± 14 91.9 ± 10.7 .799 .372 93.4 ± 11.3 93.4 ± 12.5 89.5 ± 11.8 2.47 .087
Waist-hip ratio .9 ± .1 .9 ± .1 .9 ± .09 .141 .708 .96 ± .07 .98 ± .18 .93 ± .09 3.62 .029
VCO2 (mL/min) 221 ± 42.4 231.3 ± 44.3 216.8 ± 41 3.690 .057 235.3 ± 42.6 223.7 ± 47.6 204.9 ± 34.5 8.64 <.001
VO2 (mL/min) 265.3 ± 48.3 279.7 ± 48.4 259.8 ± 47.4 6.489 .012 283.5 ± 50.7 264.3 ± 48 249.2 ± 41 10.44 <.001
RQ .83 ± .06 .83 ± .07 .84 ± .06 .066 .797 .84 ± .08 .84 ± .04 .84 ± .05 .008 .992
REE (kCal/24 h) 1819.1 ± 357 1897 ± 320 1789.8 ± 367 1.128 .290 1965.3 ± 357 1838.8 ± 344 1691.2 ± 320 13.05 <.001
REE/Lean Mass 121.0 ± 62.7 129.1 ± 58.2 117.8 ± 64.3 1.157 .284 142.5 ± 72.9 94.5 ± 38.2 113.1 ± 56.1 7.516 .001
Glycemia, Insulin
Sensitivity
Insulinogenic Index .59 ± .4 .62 ± .4 .64 ± .4 .093 .761 .59 ± .5 .56 ± .3 .60 ± .4 1.064 .347
HOMA-IR 3.3 ± 3.9 3.5 ± 4.1 3.3 ± 3.9 .061 .805 3.3 ± 3.7 2.9 ± 2.3 3.5 ± 4.7 .329 .720
Fasting glucose (mg/dl) 94.7 ± 14.2 95 ± 14.03 94.6 ± 14.4 .037 .848 93.1 ± 8.6 97.8 ± 22.8 94.8 ± 14 1.266 .284
OGTT Glucose 120 min
(mg/dl)
127.9 ± 41.7 124.7 ± 47.7 129.1 ± 39.4 .436 .510 121.6 ± 37.6 143.4 ± 51.4 127.1 ± 40.3 3.126 .046
Fasting Insulin (μU/ml) 15.4 ± 25.6 14.7 ± 18.6 15.6 ± 27.8 .048 .827 14.5 ± 17.2 20.1 ± 49.7 14.5 ± 17.8 .653 .522
OGTT Insulin 120 min
(μU/ml)
83.7 ± 76 75.1 ± 74.3 86.8 ± 76.7 .903 .343 63.3 ± 56.9 81.4 ± 58 101.9 ± 90.9 5.424 .005
HbA1c (%) 5.3 ± .6 5.3 ± .6 5.3 ± .56 .174 .677 5.3 ± .45 5.69 ± .74 5.22 ± .57 8.207 <.001
Data are mean ± SE or percent.
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(P < 0.001) levels. Hispanics had higher insulin levels
at 90 min and 120 min of the OGTT than NHW’s or
African-Americans. No ethnic difference was noted in
calculated measures of insulin resistance such as area
under the curve (AUC) for insulin or the insulino-
genic index.
A linear regression model was fitted to determine
parameters associated with HbA1c, fasting glucose and
2-hour glucose (Table 2a). Fasting glucose, age, female
sex and ethnicity were significant predictors of HbA1c
(R2 = 0.395; F < .001). After adjusting for known con-
founders, HbA1c was significantly higher among African-
Americans and Hispanics than among NHWs. After
adjusting for confounders, fasting glucose levels were pre-
dicted only weakly by the Homeostasis Model Assessment
measure of insulin resistance (HOMA-IR) and by PI use
(R2 = 0.153; F = .012). However, 2-hour glucose level
(adjusted) was strongly and significantly predicted by
age, female sex, ethnicity and fasting glucose, (R2 = 0.565;
F < .001). Hispanics and African-Americans had signi-
ficantly higher 2-hour glucose levels than NHW’s. In the
regression model, for the 2-hour glucose level, the signi-
ficant interaction effect of ethnicity with fasting glucose
(P < 0.001) highlighted differences among the three ethnic
groups (NHW’s < African Americans <Hispanics) in this
glycemic parameter. Outcomes of the regression model
for the glucose response curves in the OGTT are shown
in Table 2b. Age, female sex, HOMA-IR and AUC insulin
were significant predictors in the model (R2 = 0.392;
F < 0.001). There was a significant interaction of ethnicity
with CD4 strata.
Multivariate analysis (repeated measures ANOVA)
assessed the effect of ethnicity on the OGTT glucose re-
sponse curves after controlling for confounders (age,
sex, race, obesity, fasting glucose, HOMA-IR, family his-
tory of diabetes, blood pressure, duration of HIV, and PI
drug use) and also measured interactions of ethnicity
with age, sex and CD4 strata. Ethnicity alone did not dis-
tinguish the glucose response curves in a statistically
significant manner. Interaction effects of ethnicity*sex,
and ethnicity*age were also not significant, but an
interaction between ethnicity and CD4 strata was sig-
nificant for the glucose response curves (P = 0.023).
Interaction effects of ethnicity with CD4 count imply
that the effect of ethnicity is modified by the CD4
count of the subjects. To elucidate how ethnicity af-
fects the relationship between glycemic excursions and
CD4 levels, we plotted post-challenge glucose data
against ethnic groups for each CD4 stratum (Figure 1).
In the moderate-high CD4 group, Hispanic subjects had
the highest mean post-challenge glycemic excursion
(Figure 1a), while in the low CD4 group, African-
Americans had the highest mean post-challenge gly-
cemic excursion (Figure 1b).
Discussion
This is the first study to assess ethnic differences in
glycemic parameters among HIV patients on a stable
HAART regimen, specifically those with hypertriglyc-
eridemia. The selection criteria for the Heart Positive
study permitted us to investigate metabolic factors that
differentiate glycemic control between ethnic groups of
HIV patients without a history of diabetes, and to analyze
a large data set of both fasting and post-prandial glucose
responses. In bivariate analyses, African-Americans, His-
panics and NHW’s had similar fasting glucose levels, but
African-Americans had higher HbA1c and 2-hour OGTT
glucose values than Hispanics and NHWs. Significant
Table 2 Multivariate regression models: factors
associated with (a) HbA1c, Fasting Glucose, 2-Hour
Glucose, and (b) glucose response curves in the OGTT
Variable Standardized
Regression Coefficient
P-value
HbA1c R2 = 0.395
(a)
Fasting Glucose .533 .011
Female (versus male) .356 .005
Age .193 .003
Ethnic Category 301 .038
White Referent
African American .322 .005
Hispanic .167 .039
Fasting Glucose R2 = 0.153
HOMA-IR .325 <.001
PI Drug -.154 .050
2-Hour Glucose R2 = 0.565
Fasting Glucose .325 .010
Age .292 .032
Female (versus male) .360 .003
HOMA-IR .141 .005
Ethnic Category .146 <.001
White Referent group
African American -.126 .014
Hispanic -.380 <.001
Ethnicity*Fasting Glucose .165 <.001
(b)
Glucose Response
Curves in OGTT
R2 = 0.392
Age .276 <.001
Female (versus male) .106 .051
HOMA-IR .136 .062
AUC Insulin .145 .080
Ethnicity *CD4 -172 .023
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ethnic differences noted in the multivariate models for
2-hour glucose and HbA1c suggested that ethnicity affects
postprandial glycemic control in HIV patients on HAART.
These effects persisted after adjusting for group differ-
ences in age, sex, HIV years, HAART years, smoking,
obesity, fasting glucose, fasting insulin, and lipid levels.
Overall, African-Americans and Hispanics had higher
glucose values after oral glucose challenge as well as
higher HbA1c levels than NHW’s, and an interaction
between ethnicity and CD4 count modulated the gly-
cemic response.
A previous study demonstrated that HIV-infected
African American women have higher HbA1c levels than
NHWs [10]. While controlling for ethnicity, age and CD4
count provided a reasonably accurate reflection of gly-
cemic control in that study, the present results indicate
that the greater impairment in glycemic control among
HIV infected African-Americans is not due to unmea-
sured or suboptimally measured risk factors. A robust
model that included all possible risk factors (demographic,
anthropometric, clinical, and metabolic parameters) im-
proved our confidence in the existence of ethnic dispar-
ities in specific glycemic parameters in this cohort who
are at high risk for metabolic complications. It is possible
that the effect of ethnicity in part “pre-dated” HIV in-
fection or HAART therapy, since African American and
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Figure 1 Glucose response curves for HIV-infected African-Americans, Hispanics and NHW’s in the oral glucose tolerance test.
Multivariate models revealed a significant interaction between ethnicity and CD4+ T cell stratum that affected the glucose response curves
(P = 0.023). a. Glucose response curves of patients with CD4+ T cell counts≥ 300/cc on stable HAART; b. Glucose response curves of patients
with CD4+ T cell counts < 300/cc on stable HAART.
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Hispanics the general US population is known to have in-
creased risk for impaired glucose tolerance and diabetes
compared to NHW’s. The cross-sectional design of this
study and absence of a HIV-negative control group did
not permit us to estimate the specific effects of HIV /
HAART on the risk of dysglycemia. However the inter-
action between ethnicity and CD4 level suggests that spe-
cific effects related to the immune status resulting from
chronic HIV infection and its treatment magn ify the risk
of dysglycemia in minority ethnic groups.
Previous studies have shown inconsistent associations
of CD4 cell count with abnormal glucose levels in HIV
patients. Low CD4 cell count was associated with IGT
and diabetes in patients co-infected with HIV, hepatitis
C and hepatitis B virus [16]. Estrada et al. reported that
patients with HIV-associated lipodystrophy and IGT
have lower CD4 counts than normoglycemic patients
[17]. El-Sadr et al. found an inverse relationship between
CD4 counts and insulin resistance in HIV patients [18],
but no relationship between CD4 counts and fasting
glucose concentrations. This finding is consistent with
our data which showed CD4-related differences relate to
post-challenge glucose levels, not to fasting glucose
levels. Shikuma et al. reported no association between
fasting glucose levels and CD4 levels but did not meas-
ure post-challenge glucose [19]. In contrast to our re-
sults demonstrating no differences in either fasting or
post-challenge insulin levels, these investigators also
noted that their small sample (7–8 subjects in the respect-
ive groups) of HIV patients with CD4 <200/cc had higher
fasting insulin levels than those with CD4 >500/cc.
The design of this study makes it difficult to specify
the reasons for the relationships between ethnicity, CD4
counts and glucose tolerance in these patients. However,
the literature suggests potential mechanisms that should
be investigated in future studies. Strictly speaking these
results may be generalizable to only to HIV patients with
hypertriglyceridemia, however such patients comprise a
large proportion of those with HIV infection on various
forms of antiretroviral therapy. Additional limitations in-
clude the fact that not all ART drug classes or single
drugs that could possibly affect insulin sensitivity were
included in the multivariate analyses. However, drugs of
the protease inhibitor class (which are the most strongly
associated with both insulin resistance and defects in
glucose uptake) were taken into consideration (i.e., use
of PI was controlled for in the analyses).
Abnormal glycemic responses following an oral glu-
cose challenge could be due to insulin resistance or im-
paired insulin secretion. HOMA-IR, a marker of insulin
resistance calculated from fasting values of glucose and
insulin, did not differ between patients of the different
CD4 strata, suggesting that an aspect of the glycemic de-
fect might involve defective insulin response to an oral
challenge. Consistent with this notion, AUC insulin fol-
lowing the oral challenge and the insulinogenic index
(a measure of insulin response relative to the glucose
surge) did not differ between the two CD4 strata, indicat-
ing that persons with both low and high CD4 cell counts
may have inadequate insulin secretory response in the face
of higher post-challenge glucose levels. It is possible that
either low or high CD4 levels might reflect underlying im-
munologic mechanisms that could affect beta cell mass or
function. These possibilities are supported by recent stud-
ies showing that, compared to healthy non-HIV persons,
HIV patients have higher rates of IGT [20] without neces-
sarily having greater degrees of insulin resistance [21].
While the CD4+ T cell level (low or moderate-high)
achieved on a stable HAART regimen was not by itself
associated with dysglycemia, ethnicity appeared to inter-
act with low or moderate-high CD4 levels to affect gly-
cemic response to an oral glucose challenge. Activated
CD4 cells play a significant role in non-insulin mediated
glucose disposal [22]. The association of dysglycemia
with low CD4 levels could be due to impaired non-
insulin mediated glucose disposal caused by a dimi-
nished “sink” of activated CD4 cells (normally equal in
total mass to perhaps a third of the liver) or to a greater
degree of chronic systemic inflammation. Association of
defective glucose disposal with high CD4 counts might
be due to post-HAART recovery of CD4 T cells that
are unable to utilize glucose effectively because of low
GLUT-1 or IL7-R expression or to the influence of gen-
etic factors such as CCL3L1 or CCR5 polymorphisms
known to be associated with the development of type 1
diabetes [23]. These findings will be important in formu-
lating hypotheses for an immunologic or molecular basis
of impaired glucose metabolism in HIV patients.
These findings have prominent implications for cli-
nical practice. Ethnicity should be considered to affect
risk for developing dysglycemia and Metabolic Syn-
drome among HIV patients. In the U.S., the dispropor-
tionately higher burden of HIV/AIDS coupled with the
projected population growth among African Americans
and Hispanics underscore the need for early screening
and intervention as a cost-effective public health strategy
[24,25]. Consistent with non-HIV population data [26],
we found that African-American ethnicity is associated
with IGT, both independently and through an inter-
action with low CD4 count. Earlier studies investigating
the association of ethnicity with IGT or insulin resis-
tance in HIV patients have shown inconsistent results.
NHW ethnicity, Hispanic ethnicity, and non-Caucasian
race each have been shown to increase risk for insulin
resistance or IGT [11]. However, El-Sadr et al. [18] act-
ually found an inverse relationship between African-
American ethnicity and insulin resistance in a large HIV
cohort, while the Nutrition For Healthy Living study
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found no relation between ethnicity and insulin resistance
in HIV patients [21]. These studies involved predomin-
antly NHW’s [18], whereas our cohort had a mixed ethnic
distribution resembling that of the overall US population.
Development of ethnically focused and culturally ap-
propriate treatment approaches is highly relevant to cli-
nical management of the growing HIV epidemic among
minorities. The rate of African Americans living with
HIV infection (1,202.2) is 8 times higher than that of
NHWs (156.7) and 3 times higher than that of Hispanics
(487.3) per 100,000 population [24]. HIV’s economic
burden is predicted to grow markedly, based on the
projected dramatic increase in the minority population
as well as in HIV infections and complications associ-
ated with HAART [27]. In this context, the present
findings in a large, multiethnic cohort of hypertrigly-
ceridemic but otherwise apparently healthy HIV patients
on stable HAART have important clinical implications
for targeted therapy of HIV/HAART-associated gly-
cemic complications.
Conclusion
Among hypertriglyceridemic HIV patients on HAART,
African-Americans and Hispanics are at increased risk
of developing diabetes. Ethnicity also interacts with
CD4+ T cell count attained on stable HAART to affect
post-challenge glycemic response. Clinicians should un-
derstand ethnic-specific factors in developing treatment
strategies for dysglycemia, and should be aware of the
need for vigilant screening and possibly earlier treat-
ment for HIV-infected African-Americans with low
CD4 count and Hispanics with high CD4 count fol-
lowing HAART.
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